OptimizeRx Corp. OPRX 深 滬
等待開盤 12-13 09:30:00 美东时间
13.36
-0.670
-4.78%
華盛通- 最 高14.25
- 今 開14.05
- 成交量 21.67万股
- 最 低 13.34
- 昨 收 14.03
- 總市值 2.48亿
- 52周最高 22.25
- 市盈率 靜 --
- 換手率 1.17%
- 52周最低 3.9914
- 委 比 91.07%
- 總股本 1856.50万
- 歷史最高 99.178
- 量 比 0.75
- 振 幅 6.49%
- 歷史最低 3.78
- 每 手 1
- 風險率 5.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jim Lang Elected to Halozyme's Board of Directors
SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than ...
12-09 05:05
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $17
Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $20 to $17.
11-17 20:55
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Citizens Maintains Market Outperform on OptimizeRx, Raises Price Target to $24
Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $23 to $24.
11-07 22:07
OptimizeRx Raises FY2025 Sales Guidance from $104.000M-$108.000M to $105.000M-$109.000M vs $106.506M Est
OptimizeRx (NASDAQ:OPRX) raises FY2025 sales outlook from $104.000 million-$108.000 million to $105.000 million-$109.000 million vs $106.506 million estimate.
11-07 05:03
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
JMP Securities Maintains Market Outperform on OptimizeRx, Raises Price Target to $23
JMP Securities analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $20 to $23.
10-10 20:51
